Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections

Clinical and Vaccine Immunology

Volumn 15, Issue 3, 2008, Pages 460-467

  Swenson, Dana L ^a   Wang, Danher ^b   Luo, Min ^b   Warfield, Kelly L ^a   Woraratanadharm, Jan ^b   Holman, David H ^b   Dong, John Y ^b,c   Pratt, William D ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b GenPhar Inc   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COMPLEX ADENOVIRUS PANFILOVIRUS VACCINE; GAMMA GLUTAMYLTRANSFERASE; PROTEIN EBO2; PROTEIN EBO7; PROTEIN M11; PROTEIN M8; VIRUS VACCINE; EBOLA VACCINE; VIRUS ANTIGEN;

ADENOVIRUS; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BIOLOGICAL WARFARE; BODY FLUID; CONTROLLED STUDY; DRUG EFFICACY; EBOLA VIRUS; EPIDEMIC; FEASIBILITY STUDY; FILOVIRUS; HEMORRHAGIC FEVER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFECTION PREVENTION; LETHALITY; MARBURG VIRUS; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; TECHNOLOGY; VIRUS INFECTION; VIRUS STRAIN; VIRUS TYPING; ANIMAL; CLASSIFICATION; FILOVIRIDAE; GENE VECTOR; GENETICS; IMMUNOLOGY; MACACA; METABOLISM; PATHOGENICITY; VIRUS HEMORRHAGIC FEVER;

ADENOVIRIDAE; ANIMALS; ANTIGENS, VIRAL; BIOTERRORISM; EBOLA VACCINES; EBOLAVIRUS; FILOVIRIDAE; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA FASCICULARIS; MARBURG VIRUS DISEASE; MARBURGVIRUS; VIRAL VACCINES;

EID: 42049102862     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00431-07     Document Type: Article

References (48)

1. Alibek, K., and H. Handelman. 1999. Biohazard. Random House, New York, NY.
2. Appaiahgari, M. B., M. Saini, M. Rauthan, Jyoti, and S. Vrati. 2006. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect. 8:92-104.
3. Bermejo, M., J. D. Rodriguez-Teijeiro, G. Illera, A. Barroso, C. Vila, and P. D. Walsh. 2006. Ebola outbreak killed 5000 gorillas. Science 314:1564.
4. Capone, S., A. Meola, B. B. Ercole, A. Vitelli, M. Pezzanera, L. Ruggeri, M. E. Davies, R. Tafi, C. Santini, A. Luzzago, T. M. Fu, A. Bett, S. Colloca, R. Cortese, A. Nicosia, and A. Folgori. 2006. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 80:1688-1699.
5. Casimiro, D. R., L. Chen, T. M. Fu, R. K. Evans, M. J. Caulfield, M. E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, D. C. Freed, K. A. Wilson, S. Dubey, D. M. Zhu, D. Nawrocki, H. Mach, R. Troutman, L. Isopi, D. Williams, W. Hurni, Z. Xu, J. G. Smith, S. Wang, X. Liu, L. Guan, R. Long, W. Trigona, G. J. Heidecker, H. C. Perry, N. Persaud, T. J. Toner, Q. Su, X. Liang, R. Youil, M. Chastain, A. J. Bett, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313.
6. Chirmule, N., K. Propert, S. Magosin, Y. Qian, R. Qian, and J. Wilson. 1999. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6:1574-1583.
7. Cohen, P. 2006. Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response. IAVI Rep. 10(1):1-5.
8. Daddario-DiCaprio, K. M., T. W. Geisbert, U. Stroher, J. B. Geisbert, A. Grolla, E. A. Fritz, L. Fernando, E. Kagan, P. B. Jahrling, L. E. Hensley, S. M. Jones, and H. Feldmann. 2006. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367:1399-1404.
9. Feldmann, H., S. M. Jones, K. M. Daddario-DiCaprio, J. B. Geisbert, U. Stroher, A. Grolla, M. Bray, E. A. Fritz, L. Fernando, F. Feldmann, L. E. Hensley, and T. W. Geisbert. 2007. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 3:e2.
10. Feldmann, H., T. W. Geisbert, P. B. Jahrling, H.-D. Klenk, S. V. Netesov, C. J. Peters, A. Sanchez, R. Swanepoel, and V. E. Volchkov. 2005. Family Filoviridae, p. 645-653. In C. M. Fauquet, M. A. Mayo, J. Maniloff, U. Desselberger, and L. A. Ball (ed.), Virus taxonomy: classification and nomenclature. Eighth report of the International Committee on Taxonomy of Viruses. Elsevier Academic Press, San Diego, CA.
11. Geisbert, T. W., L. E. Hensley, T. Larsen, H. A. Young, D. S. Reed, J. B. Geisbert, D. P. Scott, E. Kagan, P. B. Jahrling, and K. J. Davis. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163:2347-2370.
12. Geisbert, T. W., P. Pushko, K. Anderson, J. Smith, K. J. Davis, and P. B. Jahrling. 2002. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8:503-507.
13. Hashimoto, M., J. L. Boyer, N. R. Hackett, J. M. Wilson, and R. G. Crystal. 2005. Induction of protective immunity to anthrax lethal toxin with a non-human primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect. Immun. 73:6885-6891.
14. Hevey, M., D. Negley, J. Geisbert, P. Jahrling, and A. Schmaljohn. 1997. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 239:206-216.
15. Hevey, M., D. Negley, P. Pushko, J. Smith, and A. Schmaljohn. 1998. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251:28-37.
16. Hevey, M., D. Negley, L. VanderZanden, R. F. Tammariello, J. Geisbert, C. Schmaljohn, J. F. Smith, P. B. Jahrling, and A. L. Schmaljohn. 2001. Marburg virus vaccines: comparing classical and new approaches. Vaccine 20:586-593.
17. Holman, D. H., D. Wang, K. Raviprakash, N. U. Raja, M. Luo, J. Zhang, K. R. Porter, and J. Y. Dong. 2007. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin. Vaccine Immunol. 14:182-189.
18. Jaax, N., P. Jahrling, T. Geisbert, J. Geisbert, K. Steele, K. McKee, D. Nagley, E. Johnson, G. Jaax, and C. Peters. 1995. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346:1669-1671.
19. Johnson, E., N. Jaax, J. White, and P. Jahrling. 1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76:227-236.
20. Johnson, E. D., B. K. Johnson, D. Silverstein, P. Tukei, T. W. Geisbert, A. N. Sanchez, and P. B. Jahrling. 1996. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. Suppl. 11:101-114.
21. Jones, S. M., H. Feldmann, U. Stroher, J. B. Geisbert, L. Fernando, A. Grolla, H. D. Klenk, N. J. Sullivan, V. E. Volchkov, E. A. Fritz, K. M. Daddario, L. E. Hensley, P. B. Jahrling, and T. W. Geisbert. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786-790.
22. Kanesa-thasan, N., W. Sun, G. Kim-Ahn, S. Van Albert, J. R. Putnak, A. King, B. Raengsakulsrach, H. Christ-Schmidt, K. Gilson, J. M. Zahradnik, D. W. Vaughn, B. L. Innis, J. F. Saluzzo, and C. H. Hoke, Jr. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19:3179-3188.
23. Kobinger, G. P., H. Feldmann, Y. Zhi, G. Schumer, G. Gao, F. Feldmann, S. Jones, and J. M. Wilson. 2006. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346:394-401.
24. Leffel, E. K., and D. S. Reed. 2004. Marburg and Ebola viruses as aerosol threats. Biosecur. Bioterror. 2:186-191.
25. Moe, J. B., R. D. Lambert, and H. W. Lupton. 1981. Plaque assay for Ebola virus. J. Clin. Microbiol. 13:791-793.
26. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
27. Ndayimirije, N., and M. K. Kindhauser. 2005. Marburg hemorrhagic fever in Angola-fighting fear and a lethal pathogen. N. Engl. J. Med. 352:2155-2157.
28. Nwanegbo, E., E. Vardas, W. Gao, H. Whittle, H. Sun, D. Rowe, P. D. Robbins, and A. Gambotto. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
29. Raja, N. U., D. H. Holman, D. Wang, K. Raviprakash, L. Y. Juompan, S. B. Deitz, M. Luo, J. Zhang, K. R. Porter, and J. Y. Dong. 2007. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. Am. J. Trop. Med. Hyg. 76:743-751.
30. Rubinchik, S., J. S. Norris, and J. Y. Dong. 2002. Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol. 346:529-547.
31. Rubinchik, S., D. Wang, H. Yu, F. Fan, M. Luo, J. S. Norris, and J. Y. Dong. 2001. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol. Ther. 4:416-426.
32. Rubinchik, S., J. Woraratanadharm, J. Schepp, and J. Y. Dong. 2003. Improving the transcriptional regulation of genes delivered by adenovirus vectors. Methods Mol. Med. 76:167-199.
33. Schepp-Berglind, J., M. Luo, D. Wang, J. A. Wicker, N. U. Raja, B. D. Hoel, D. H. Holman, A. D. Barrett, and J. Y. Dong. 2007. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin. Vaccine Immunol. 14:1117-1126.
34. Slenczka, W. G. 1999. The Marburg virus outbreak of 1967 and subsequent episodes. Curr. Top. Microbiol. Immunol. 235:49-75.
35. Smith, D. H., B. K. Johnson, M. Isaacson, R. Swanapoel, K. M. Johnson, M. Killey, A. Bagshawe, T. Siongok, and W. K. Keruga. 1982. Marburg-virus disease in Kenya. Lancet i:816-820.
36. Sullivan, N. J., T. W. Geisbert, J. B. Geisbert, L. Xu, Z. Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684.
37. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
38. Swenson, D. L., K. L. Warfield, D. L. Negley, A. Schmaljohn, M. J. Aman, and S. Bavari. 2005. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23:3033-3042.
39. Van Kampen, K. R., Z. Shi, P. Gao, J. Zhang, K. W. Foster, D. T. Chen, D. Marks, C. A. Elmets, and D. C. Tang. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036.
40. Wang, D., M. Hevey, L. Y. Juompan, C. M. Trubey, N. U. Raja, S. B. Deitz, J. Woraratanadharm, M. Luo, H. Yu, B. M. Swain, K. M. Moore, and J. Y. Dong. 2006. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology 353:324-332.
41. Wang, D., N. U. Raja, C. M. Trubey, L. Y. Juompan, M. Luo, J. Woraratanadharm, S. B. Deitz, H. Yu, B. M. Swain, K. M. Moore, W. D. Pratt, M. K. Hart, and J. Y. Dong. 2006. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J. Virol. 80:2738-2746.
42. Wang, D., A. L. Schmaljohn, N. U. Raja, C. M. Trubey, L. Y. Juompan, M. Luo, S. B. Deitz, H. Yu, J. Woraratanadharm, D. H. Holman, K. M. Moore, B. M. Swain, W. D. Pratt, and J. Y. Dong. 2006. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine 24:2975-2986.
43. Warfield, K. L., C. M. Bosio, B. C. Welcher, E. M. Deal, M. Mohamadzadeh, A. Schmaljohn, M. J. Aman, and S. Bavari. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. USA 100:15889-15894.
44. Warfield, K. L., D. L. Swenson, D. L. Negley, A. L. Schmaljohn, M. J. Aman, and S. Bavari. 2004. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 22:3495-3502.
45. Wilson, J. A., and M. K. Hart. 2001. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol. 75:2660-2664.
46. World Health Organization. 1978. Ebola haemorrhagic fever in Sudan, 1976: report of a WHO/international study team. Bull. W. H. O. 56:247-270.
47. World Health Organization. 2007. Outbreak news. Ebola virus haemorrhagic fever, Democratic Republic of the Congo-update. Wkly. Epidemiol. Rec. 82:345-346.
48. Xiang, Z. Q., G. P. Gao, A. Reyes-Sandoval, Y. Li, J. M. Wilson, and H. C. Ertl. 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77:10780-10789.